{"transactions":[{"id":723016,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T20:06:30.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":2875,"derivative":{"exercise_price":3.85,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":2875},"source":{"system":"sec-edgar","filing":"0001219866-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000121986626000002/ownership.xml","form_type":"4"}},{"id":723015,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T20:06:30.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the \"Reverse Stock Split\"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split."}],"balance_after":11750,"source":{"system":"sec-edgar","filing":"0001219866-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000121986626000002/ownership.xml","form_type":"4"}},{"id":1099478,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-30T20:06:37.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":23000,"derivative":{"exercise_price":0.74,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0000950170-25-091555","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017025091555/ownership.xml","form_type":"4"}},{"id":1099477,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-30T20:06:37.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":71000,"source":{"system":"sec-edgar","filing":"0000950170-25-091555","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017025091555/ownership.xml","form_type":"4"}},{"id":1472325,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-21T20:03:46.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":23000,"derivative":{"exercise_price":1.88,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0000950170-24-076203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017024076203/ownership.xml","form_type":"4"}},{"id":1472324,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:03:46.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":48000,"source":{"system":"sec-edgar","filing":"0000950170-24-076203","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017024076203/ownership.xml","form_type":"4"}},{"id":1761727,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-11T13:52:29.000Z","date":"2023-10-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":190000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 7)"},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"(Continued from footnote 6) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 7)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"(Continued from footnote 6) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment."}],"balance_after":0,"derivative":{"exercise_price":2.41,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001140361-23-047723","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000114036123047723/form4.xml","form_type":"4"}},{"id":1761726,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-10-11T13:52:29.000Z","date":"2023-10-10","kind":"other","planned":false,"acquired":false,"shares":13297,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation (\"Parent\") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub completed a tender offer (the \"Offer\") for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the \"Effective Time\" with the Issuer surviving the merger). (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the \"Cash Amount\") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a \"CVR\") per Share (the \"CVR Amount\" and together with the Cash Amount, the \"Merger Consideration\"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a \"Milestone Payment\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-047723","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000114036123047723/form4.xml","form_type":"4"}},{"id":1761725,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-10-11T13:52:29.000Z","date":"2023-10-10","kind":"other","planned":false,"acquired":false,"shares":26595,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation (\"Parent\") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub completed a tender offer (the \"Offer\") for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the \"Effective Time\" with the Issuer surviving the merger). (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the \"Cash Amount\") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a \"CVR\") per Share (the \"CVR Amount\" and together with the Cash Amount, the \"Merger Consideration\"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a \"Milestone Payment\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-047723","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000114036123047723/form4.xml","form_type":"4"}},{"id":1761724,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-10-11T13:52:29.000Z","date":"2023-10-10","kind":"other","planned":false,"acquired":false,"shares":610000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This line item represents unvested RSAs held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This line item represents unvested RSAs held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-047723","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000114036123047723/form4.xml","form_type":"4"}},{"id":1761723,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-10-11T13:52:29.000Z","date":"2023-10-10","kind":"grant","planned":false,"acquired":true,"shares":240000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This line item represents unvested restricted stock awards (\"RSAs\") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This line item represents unvested restricted stock awards (\"RSAs\") with performance-based vesting previously granted to the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest"}],"balance_after":610000,"source":{"system":"sec-edgar","filing":"0001140361-23-047723","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000114036123047723/form4.xml","form_type":"4"}},{"id":1761722,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-10-11T13:52:29.000Z","date":"2023-10-10","kind":"other","planned":false,"acquired":false,"shares":566722,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation (\"Parent\") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub completed a tender offer (the \"Offer\") for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the \"Effective Time\" with the Issuer surviving the merger). (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the \"Cash Amount\") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a \"CVR\") per Share (the \"CVR Amount\" and together with the Cash Amount, the \"Merger Consideration\"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a \"Milestone Payment\")."}],"balance_after":370000,"source":{"system":"sec-edgar","filing":"0001140361-23-047723","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000114036123047723/form4.xml","form_type":"4"}},{"id":1780872,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-09-14T20:13:06.000Z","date":"2023-09-13","kind":"sale","planned":false,"acquired":false,"shares":17830,"price":1.3257,"value":23637.231,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":936722,"source":{"system":"sec-edgar","filing":"0001062993-23-018018","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000106299323018018/form4.xml","form_type":"4"}},{"id":1780871,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-09-14T20:13:06.000Z","date":"2023-09-12","kind":"grant","planned":false,"acquired":true,"shares":64747,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 64,747 performance-based restricted stock awards granted in a prior year."}],"balance_after":954552,"source":{"system":"sec-edgar","filing":"0001062993-23-018018","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000106299323018018/form4.xml","form_type":"4"}},{"id":1845519,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-23T20:15:25.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0000950170-23-029630","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017023029630/ownership.xml","form_type":"4"}},{"id":1850100,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-06-20T23:58:14.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":2.74,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-23-029034","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000095017023029034/ownership.xml","form_type":"4"}},{"id":2024498,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-02-09T22:10:27.000Z","date":"2023-02-08","kind":"tax_withholding","acquired":false,"shares":12547,"price":0.5965,"value":7484.2855,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":889805,"source":{"system":"sec-edgar","filing":"0000899243-23-004442","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000089924323004442/doc4.xml","form_type":"4"}},{"id":2024497,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-02-09T22:10:27.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":45406,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock award was granted in lieu of a portion of a cash bonus earned by the Reporting Person and fully vested as of the grant date."}],"balance_after":902352,"source":{"system":"sec-edgar","filing":"0000899243-23-004442","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000089924323004442/doc4.xml","form_type":"4"}},{"id":2035514,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-02-03T01:13:51.000Z","date":"2023-02-01","kind":"tax_withholding","acquired":false,"shares":11726,"price":0.5952,"value":6979.3152,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":856946,"source":{"system":"sec-edgar","filing":"0000899243-23-003732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000089924323003732/doc4.xml","form_type":"4"}},{"id":2035513,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-02-03T01:13:51.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":42437,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock award was granted in lieu of a portion of a cash bonus earned by the Reporting Person and fully vested as of the grant date."}],"balance_after":868672,"source":{"system":"sec-edgar","filing":"0000899243-23-003732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000089924323003732/doc4.xml","form_type":"4"}},{"id":2046274,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:25:25.000Z","date":"2023-01-24","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock award will fully vest in two installments, subject to continued employment with the Company through the applicable vesting date: 1/3 of the restricted stock will vest on February 1, 2024; and 2/3 of the restricted stock will vest on February 1, 2025."}],"balance_after":826235,"source":{"system":"sec-edgar","filing":"0001062993-23-001384","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000106299323001384/form4.xml","form_type":"4"}},{"id":2046273,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2023-01-25T22:25:25.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":35453,"price":0.5978,"value":21193.8034,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":576235,"source":{"system":"sec-edgar","filing":"0001062993-23-001384","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000106299323001384/form4.xml","form_type":"4"}},{"id":2204472,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CEO"}}],"security":"Common Stock","published_at":"2022-07-20T20:05:23.000Z","date":"2022-07-19","kind":"sale","acquired":false,"shares":11899,"price":1.1,"value":13088.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person."}],"balance_after":611688,"source":{"system":"sec-edgar","filing":"0001062993-22-016555","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000106299322016555/form4.xml","form_type":"4"}},{"id":2204471,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CEO"}}],"security":"Common Stock","published_at":"2022-07-20T20:05:23.000Z","date":"2022-07-18","kind":"grant","acquired":true,"shares":43164,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 18, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 43,164 performance-based restricted stock awards granted in a prior year."}],"balance_after":623587,"source":{"system":"sec-edgar","filing":"0001062993-22-016555","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000106299322016555/form4.xml","form_type":"4"}},{"id":2224415,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T20:01:50.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":1.78,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-038652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919122038652/doc4.xml","form_type":"4"}},{"id":2224414,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-22T20:01:50.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-22-038652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919122038652/doc4.xml","form_type":"4"}},{"id":2422330,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-28T21:28:15.000Z","date":"2022-01-26","kind":"grant","acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date."}],"balance_after":190000,"derivative":{"exercise_price":2.41,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001062993-22-001787","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000106299322001787/form4.xml","form_type":"4"}},{"id":2422329,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2022-01-28T21:28:15.000Z","date":"2022-01-26","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award will fully vest on January 26, 2024, subject to continued employment with the Company through the applicable vesting date."}],"balance_after":580423,"source":{"system":"sec-edgar","filing":"0001062993-22-001787","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000106299322001787/form4.xml","form_type":"4"}},{"id":2661558,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T12:27:37.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":7.51,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-041821","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919121041821/doc4.xml","form_type":"4"}},{"id":2766652,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T20:00:59.000Z","date":"2020-07-06","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":55000,"derivative":{"exercise_price":0.73,"expiration_date":"2030-07-05","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-21-023757","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919121023757/doc4a.xml","form_type":"4/A","original_submission_date":"2020-07-06"}},{"id":2897477,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-25T21:21:15.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":161867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests 25% on the first anniversary of the grant date, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date."}],"balance_after":161867,"derivative":{"exercise_price":3.58,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":161867},"source":{"system":"sec-edgar","filing":"0001192482-21-000113","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000119248221000113/edgar.xml","form_type":"4"}},{"id":2897476,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2021-01-25T21:21:15.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":107911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock awards will fully vest on January 21, 2023, subject to continued employment with the Company through the applicable vesting date."}],"balance_after":460423,"source":{"system":"sec-edgar","filing":"0001192482-21-000113","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000119248221000113/edgar.xml","form_type":"4"}},{"id":2933297,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant","published_at":"2020-12-23T14:02:10.000Z","date":"2020-12-21","kind":"grant","acquired":true,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase on December 21, of 5,000 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant)."}],"balance_after":2500,"derivative":{"exercise_price":8.25,"exercise_date":"2020-12-21","expiration_date":"2024-06-21","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-20-064954","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919120064954/doc4.xml","form_type":"4"}},{"id":2933296,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant","published_at":"2020-12-23T14:02:10.000Z","date":"2020-12-21","kind":"grant","acquired":true,"shares":2500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase on December 21, of 5,000 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant)."}],"balance_after":2500,"derivative":{"exercise_price":7.33,"exercise_date":"2020-12-21","expiration_date":"2021-12-21","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-20-064954","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919120064954/doc4.xml","form_type":"4"}},{"id":2933295,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-23T14:02:10.000Z","date":"2020-12-21","kind":"purchase","acquired":true,"shares":5000,"price":6.25,"value":31250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase on December 21, of 5,000 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant)."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-20-064954","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919120064954/doc4.xml","form_type":"4"}},{"id":3086791,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-08T20:07:14.000Z","date":"2020-07-06","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":0.73,"expiration_date":"2030-07-05","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-20-041731","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919120041731/doc4.xml","form_type":"4"}},{"id":3294704,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-03T21:37:20.000Z","date":"2020-01-30","kind":"grant","acquired":true,"shares":162480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 25% on the first anniversary of the grant date, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company through the applicable vesting date."}],"balance_after":162480,"derivative":{"exercise_price":5.05,"expiration_date":"2030-01-30","underlying":"Common Stock","underlying_shares":162480},"source":{"system":"sec-edgar","filing":"0001192482-20-000095","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000119248220000095/edgar.xml","form_type":"4"}},{"id":3482546,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T17:31:25.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date."}],"balance_after":45000,"derivative":{"exercise_price":1.29,"expiration_date":"2029-06-17","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001209191-19-038194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919119038194/doc4.xml","form_type":"4"}},{"id":3682459,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-30T21:12:15.000Z","date":"2019-01-24","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 25% on the first anniversary of the grant date, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Due to a clerical error, the reporting person is filing this Amendment to correct the expiration date of the stock options from 1/24/2019 to 1/24/2029."}],"balance_after":160000,"derivative":{"exercise_price":3.65,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001192482-19-000063","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000119248219000063/edgar.xml","form_type":"4/A","original_submission_date":"2019-01-28"}},{"id":3685195,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-28T21:15:15.000Z","date":"2019-01-24","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 25% on the first anniversary of the grant date, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company."}],"balance_after":160000,"derivative":{"exercise_price":3.65,"expiration_date":"2019-01-24","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001192482-19-000049","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000119248219000049/edgar.xml","form_type":"4"}},{"id":3689596,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-23T14:34:33.000Z","date":"2019-01-21","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One third of the shares subject to this option vest on the one year anniversary of the grant date, and 1/36 of the shares subject to the option vest on each of the next 24 months thereafter."}],"balance_after":70000,"derivative":{"exercise_price":0.7425,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-19-004901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178253/000120919119004901/doc4.xml","form_type":"4"}},{"id":3850633,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2018-08-07T20:32:19.000Z","date":"2018-08-06","kind":"purchase","acquired":true,"shares":15000,"price":5.9615,"value":89422.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.78 to $6.07, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4."}],"balance_after":352512,"source":{"system":"sec-edgar","filing":"0001192482-18-000386","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000119248218000386/edgar.xml","form_type":"4"}},{"id":4099203,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-01-16T21:10:20.000Z","date":"2018-01-11","kind":"grant","acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company."}],"balance_after":81000,"derivative":{"exercise_price":11.71,"expiration_date":"2028-01-11","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001192482-18-000040","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000119248218000040/edgar.xml","form_type":"4"}},{"id":4311160,"issuer":{"id":6654,"kind":"organization","name":"Vaxart, Inc."},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-22T19:30:52.000Z","date":"2017-05-18","kind":"grant","acquired":true,"shares":20000,"price":0.49,"value":9800.0,"ownership":{"direct":true},"balance_after":75000,"derivative":{"exercise_price":0.49,"exercise_date":"2018-05-18","expiration_date":"2027-05-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-17-009787","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/72444/000143774917009787/rdgdoc.xml","form_type":"4"}},{"id":4317915,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2017-05-16T12:50:47.000Z","date":"2017-05-15","kind":"purchase","acquired":true,"shares":1500,"price":19.57,"value":29355.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $19.50 to $19.70, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4."}],"balance_after":337512,"source":{"system":"sec-edgar","filing":"0001123292-17-000930","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000112329217000930/edgar.xml","form_type":"4"}},{"id":4317914,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec. Officer"}}],"security":"Common Stock","published_at":"2017-05-16T12:50:47.000Z","date":"2017-05-12","kind":"purchase","acquired":true,"shares":3500,"price":19.76,"value":69160.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $19.72 to $19.85, inclusive. The reporting person undertakes to provide Zynerba Pharmaceuticals, Inc., any security holder of Zynerba Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4."}],"balance_after":336012,"source":{"system":"sec-edgar","filing":"0001123292-17-000930","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000112329217000930/edgar.xml","form_type":"4"}},{"id":4480398,"issuer":{"id":109058,"kind":"organization","name":"Zynerba Pharmaceuticals, Inc.","symbol":"ZYNE"},"owners":[{"id":34528,"kind":"person","name":"ANIDO ARMANDO","position":1,"cik":"0001219866","reported_name":"ANIDO ARMANDO","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & Chief Exec Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-26T21:21:49.000Z","date":"2017-01-25","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company."}],"balance_after":125000,"derivative":{"exercise_price":18.22,"expiration_date":"2027-01-25","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001123292-17-000262","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1219866/000112329217000262/edgar.xml","form_type":"4"}}]}